End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H2 2019
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H2 2019
latest Pharmaceutical and Healthcare disease pipeline guide End-Stage Kidney Disease - Pipeline Review, H2 2019, provides an overview of the End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.
End-stage kidney disease is the complete or almost complete failure of the kidneys to work. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis and certain autoimmune conditions, such as lupus. Treatment includes dialysis or kidney transplant.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide End-Stage Kidney Disease - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 1, 2, 1, 1 and 1 respectively.
End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of End-Stage Kidney Disease (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
latest Pharmaceutical and Healthcare disease pipeline guide End-Stage Kidney Disease - Pipeline Review, H2 2019, provides an overview of the End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.
End-stage kidney disease is the complete or almost complete failure of the kidneys to work. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis and certain autoimmune conditions, such as lupus. Treatment includes dialysis or kidney transplant.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide End-Stage Kidney Disease - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 1, 2, 1, 1 and 1 respectively.
End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of End-Stage Kidney Disease (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
TABLE OF CONTENTS
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Companies Involved in Therapeutics Development
Aronora Inc
BioAegis Therapeutics Inc
KidneyCure Ltd
Merck & Co Inc
Novartis AG
VESSL Therapeutics Ltd
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drug Profiles
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Product Development Milestones
Appendix
Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Aronora Inc, H2 2019
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by BioAegis Therapeutics Inc, H2 2019
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by KidneyCure Ltd, H2 2019
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Merck & Co Inc, H2 2019
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Novartis AG, H2 2019
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by VESSL Therapeutics Ltd, H2 2019
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects, H2 2019
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products, H2 2019
Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Companies Involved in Therapeutics Development
Aronora Inc
BioAegis Therapeutics Inc
KidneyCure Ltd
Merck & Co Inc
Novartis AG
VESSL Therapeutics Ltd
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drug Profiles
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Product Development Milestones
Appendix
List Of Tables
Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Aronora Inc, H2 2019
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by BioAegis Therapeutics Inc, H2 2019
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by KidneyCure Ltd, H2 2019
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Merck & Co Inc, H2 2019
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Novartis AG, H2 2019
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by VESSL Therapeutics Ltd, H2 2019
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects, H2 2019
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products, H2 2019
List Of Figures
Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
RELATED REPORTS
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genitourinary Disorders) - Drugs in Development, 2021
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genitourinary Disorders) - Drugs in Development, 2021Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide End-Stage Kidney Disease - Drugs In
View ReportEnd-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H2 2020
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H2 2020 latest Pharmaceutical and Healthcare disease pipeline guide End-Stage Kidney Disease - Pipeline Review, H2 2020, provides an
View ReportKidney Disease (Nephropathy) - Global Clinical Trials Review, H2, 2021
Kidney Disease (Nephropathy) - Global Clinical Trials Review, H2, 2021GlobalDatas clinical trial report, Kidney Disease (Nephropathy) - Global Clinical Trials Review, H2, 2021 provides an overview of Kidney Disease (Nephropathy)
View ReportEnd-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genitourinary Disorders) - Drugs in Development, 2021
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genitourinary Disorders) - Drugs in Development, 2021Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide End-Stage Kidney Disease - Drugs In
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
